Trofosfamide


Concise Prescribing Info
Indications/Uses
Malignant disorders.
Dosage/Direction for Use
Adult : PO Initial: 300-400 mg/day. Maintenance: 50-150 mg/day.
Dosage Details
Oral
Malignant disease
Adult: Initially, 300-400 mg/day. Maintenance: 50-150 mg/day.
Contraindications
Pregnancy, lactation; acute infection, bone-marrow aplasia, drug or radiation-induced urothelial toxicity.
Special Precautions
Elderly and debilitated patients; renal and hepatic impairment; DM. Patients who have undergone adrenalectomy. Regular urinalysis and haematological profile may be required. Reduce urotoxicity by increasing hydration, maintaining urine output at 100 ml/hr and using mesna but care should be taken to avoid water retention and intoxication.
Adverse Reactions
Myelosuppression; thrombocytopenia, anaemia; nausea, vomiting, mucositis; alopecia; hyperpigmenation. Disturbances of carbohydrate metabolism; gonadal suppression; interstitial pulmonary fibrosis; cardiotoxicity (high doses).
Potentially Fatal: Haemorrhagic cystitis (after high dose or prolonged use).
Drug Interactions
Doxorubicin and other cardiotoxic drugs may enhance cardiotoxicity. Increased risk of bone marrow suppression with allopurinol. Increased risk of renal impairment with amphotericin B, cisplatin. Possible increase in INR with warfarin.
Action
Description: Trofosfamide, a cyclophosphamide derivative, is an alkylating agent that inhibits cell division by cross-linking DNA strands and decreasing DNA synthesis.
Disclaimer: This information is independently developed by MIMS based on Trofosfamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in